Literature DB >> 10326037

Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice.

X Cao1, D W Ju, Q Tao, J Wang, T Wan, B M Wang, W Zhang, H Hamada.   

Abstract

Antitumor effects of combined transfer of suicide and cytokine genes were investigated in this study. Adenovirus harboring E. coli cytosine deaminase gene (AdCD) and adenovirus harboring murine granulocyte-macrophage colony-stimulating factor gene (AdGMCSF) were used simultaneously for in vivo gene transfer in melanoma-bearing mice. Growth inhibition of established tumors and prolongation of survival period were observed more significantly in tumor-bearing mice after transfection with AdGMCSF and AdCD followed by continuous injection of prodrug 5-fluorocytosine (5FC) when compared with mice treated with control adenovirus AdlacZ/5FC, AdCD/5FC or AdGMCSF alone (P < 0.01). After combined therapy the expression of MHC-I (H-2Db) and B7-1 molecules on freshly isolated tumor cells increased greatly and more dendritic cells and CD8+ T cells infiltrated into the tumor mass. The activity of specific cytotoxic T lymphocytes was also found to be induced more significantly after the combined therapy. Further experiments showed that apoptosis of tumor cells and induction of antitumor immune response might be involved in the mechanisms of the tumor cell killing by the combined therapy. Our results demonstrated that combined transfer of the GM-CSF and CD suicide genes, being able to inhibit the growth of melanoma synergistically and induce specific antitumor immune response efficiently, thus addressing the drawbacks of suicide gene therapy or cytokine gene therapy which were proved to be not satisfactory when used alone, might be of therapeutic potential for gene therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10326037     DOI: 10.1038/sj.gt.3300727

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  6 in total

1.  Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.

Authors:  X Cao; W Zhang; J Wang; M Zhang; X Huang; H Hamada; W Chen
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

2.  Cytotoxic effect of co-expression of human hepatitis A virus 3C protease and bifunctional suicide protein FCU1 genes in a bicistronic vector.

Authors:  Alexey Komissarov; Ilya Demidyuk; Dina Safina; Marina Roschina; Andrey Shubin; Nataliya Lunina; Maria Karaseva; Sergey Kostrov
Journal:  Mol Biol Rep       Date:  2017-07-26       Impact factor: 2.316

3.  Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy.

Authors:  Christina Quirin; Stanimira Rohmer; Inés Fernández-Ulibarri; Michael Behr; Andrea Hesse; Sarah Engelhardt; Philippe Erbs; Alexander H Enk; Dirk M Nettelbeck
Journal:  Hum Gene Ther       Date:  2011-02-02       Impact factor: 5.695

4.  A new delivery system for 5-fluorouracil using prodrug and converting enzyme.

Authors:  M Akimoto; T Miyahara; J Arai; A Akimoto; H Hamada; Y Yoshida; N Yoshimura
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

5.  Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.

Authors:  Kyung-Sun Hwang; Won-Kyung Cho; Jinsang Yoo; Hwan-Jung Yun; Samyong Kim; Dong-Soo Im
Journal:  BMC Cancer       Date:  2005-05-24       Impact factor: 4.430

6.  Dose of adenoviral vectors expressing interleukin-2 plays an important role in combined gene therapy with cytosine deaminase/5-fluorocytosine: preclinical consideration.

Authors:  Mikihito Nakamori; Makoto Iwahashi; Kentaro Ueda; Takuya Tsunoda; Hiroshi Terasawa; Hirofumi Hamada; Hiroki Yamaue
Journal:  Jpn J Cancer Res       Date:  2002-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.